With regard to the point that studies should assess arsenic concentrations 150-500 μg/L in drinking water, there is good evidence that arsenic in water may increase the incidence of diabetes. However, every study that has produced strong evidence has included water arsenic concentrations > 500 μg/L at, or before, the time of the study. Indeed, Maull et al. (2012) cited one large, well-designed study in Bangladesh (Chen et al. 2010 ) with water arsenic concentrations up to 500 μg/L that found no evidence of increased diabetes, even among the > 2,000 participants with urinary arsenic concentrations > 200 μg/L.
In courts of law, experts may be entitled to their opinions, but in science we are not. We must focus only on the evidence and its logical interpretation. The logical interpretation of the evidence here should lead us to pursue studies in populations exposed to arsenic in drinking water in the range of 150-500 μg/L and to dismiss the notion that millions of people in the United States with very low exposure to arsenic in drinking water have major increased risks of diabetes.
In the past, I was attacked for exaggerating the effects of arsenic in drinking water, including in this journal (Carlson-Lynch et al. 1994) . Now I find myself on the other side. In 1995, it was said that epidemiology was facing its limits (Taubes 1995) ; at that time I thought these criticisms were unfair (Smith 1995) . But now epidemiology is going beyond its limits. Limited research resources should focus on biologically plausible, detectable risks, recognizing that protecting the general population which has very low exposure involves extrapolating risks downward from higher exposure studies, and accepting that we may never prove whether risk estimates at very low exposures are real or not. The goal of the National Toxicology Program (NTP) workshop review was to compre hen sively evaluate the association between arsenic and diabetes, including epidemiologic and experimental evidence (Maull et al. 2012) . Members of the arsenic breakout group carefully evaluated differences in methodologic approaches used to analyze general population studies, including NHANES (National Health Nutrition and Examination Survey) studies, trying to understand the biology and technical limitations of biomarkers of inorganic arsenic exposure measured in urine, as well as their implications for study findings. In his letter, Smith presents his arguments in a selective manner, overlooking important evidence and facts. First, multiple studies included in the NTP workshop review [see our Table 2 (Maull et al. 2012) ] support the relationship of low-to-moderate arsenic exposure levels (< 150 μg/L in drinking water) with diabetes and diabetesrelated end points. Second, when indicating that subtracting arseno betaine from total arsenic is the recommended method to evaluate inorganic arsenic exposure, Smith ignored research conducted in the last decade showing that other seafood arsenicals (arseno sugars, arseno lipids) also contribute to total urinary arsenic (European Food Safety Authority 2009; Francesconi et al. 2002; Maull et al. 2012) . Subtracting arsenobetaine from total arsenic is insufficient to eliminate the contribution of seafood arsenicals in populations where seafood is common (see Figure 1 of Maull et al. 2012) . Third, Smith criticized the adjustment of the association between total urinary arsenic and diabetes for arseno betaine without mentioning that total urinary arsenic was associated with diabetes without adjusting for arsenobetaine in NHANES participants with very low or undetectable arsenobetaine (Navas-Acien et al. 2008, 2009 ), populations where total urinary arsenic likely reflects inorganic arsenic exposure. These results at low arsenobetaine concentrations exclude collinearity as an explanation for the findings. The consistency between analyses that are restricted to very low arsenobetaine concentrations and analyses that statistically adjust for arsenobetaine is not a surprise because both epidemiologic strategies are able to minimize the contribution of other seafood arsenicals to total urine arsenic concentrations. In a transparent manner, the NTP workshop review acknowledged the differing interpretations of the NHANES studies, concluding that the lack of consistency… warrants caution in interpreting results and highlights the importance of having good analytical methods to distinguish inorganic arsenic.
As summarized in our NTP workshop review (Maull et al. 2012) , the evidence is currently insufficient to conclude that arsenic is associated with diabetes at lowto-moderate exposure levels. Limitations of many of the available studies included the lack of prospective evidence, limitations in exposure and outcome assessment, and lack of adjustment for appropriate confounders. Since the publication of the NTP workshop review, additional cross-sectional (Gribble et al. 2012 ) and prospective (James et al. 2012; Kim et al., in press) studies conducted in the United States and supporting the association between arsenic and diabetes have been published.
Millions of Americans are exposed to arsenic through drinking water and food. Smith recommended that arsenic research focus on levels in drinking water that are 15 times higher than the current safety standards of the World Health Organization, U.S. Environmental Protection Agency, and European Union. In our opinion, research and public health efforts should focus on preventing arsenic exposure. At low-to-moderate levels, state-of-theart epidemiologic tools-including costeffective designs, high quality exposure and outcome assessment, careful evaluation of dose-response relation ships, and integrated methods to evaluate gene-environment interactions and mecha nis tic pathwayscan provide insight into the health effects of arsenic exposure through drinking water and food.
